Introduction

The human aldose reductase is the protein that catalyzes the rate-limiting step in polyol pathway which generates sorbitol. Due to elevated blood glucose level (hyperglycemia) in diabetic patients, metabolism of glucose by this enzyme in the pathway may lead to biochemical imbalances causing increased intraocular pressure [1-3]. Moreover, accumulation of sorbitol within the mesangial and proximal tubule cells can lead to alterations in cellular myoinositol level [2]. It can also lower Na+/K+-ATPase activity [3,4]. Each of these effects has inherent detrimental effect in diabetes. In addition, the conversion of glucose to sorbitol requires NADPH while oxidation of sorbitol enhances NADH concentration with a concomitant rapid imbalance in the cytoplasmic redox state [4]. Therefore, a reduction in the concentration of NADPH in the cytosolic will upset the NADPH/NADP⁺ ratio. This may compromise the process which generates a reduced glutathione in oxidatively stressed cells [4,5]. Interestingly, aldose reductase inhibition can prevent or delay such numerous early alterations in hyperglycemic patient. Little wonder the enzyme has been validated as a therapeutic target in the management of diabetes and its complications.

Seaweed extracts have been reported for their diverse pharmacological and biological activities such as immunomodulating, anticoagulating, anticancer effects, etc [6-9].
Capsosiphon fulvescens (C. fulvescens) commonly known as 'Maesaengi' is a green alga widely found in the coastal area of Korea as well as along the coasts of North America and Europe [9,10]. The alga is generally eaten as food among the Koreans because of its unique flavor and soft texture as well as its acclaimed health-promoting properties. Studies have shown that it is rich in macronutrients like iron, potassium, micronutrient like iodine and vitamins (A and C) [11]. The seaweed is reportedly cultivated on a large-scale in both the laboratory and the field which enhances its economic value [12]. However, research efforts still continue till date to investigate its nutritional profile and potential therapeutic benefits [12-14].

A lot of studies carried out on C. fulvescens using in vitro and in vivo assays have unraveled the pharmacological potentials of the alga. When eaten, the seawee dis said to treat stomach disorders as well as in hangovers [11]. Extracts obtained from C. fulvescens was reported to inhibit platelet aggregation and reduce serum lipid level in ovariectomized animals [15]. The radical scavenging activities and ferric reducing ability of the seaweed extracts was reported by Cho et al. [16]. The presence of phenolic compounds and flavonoids in the sea plant was also reported and correlated with the antioxidant effectiveness of the plant. These compounds contribute to the capacity of C. fulvescens to improve lipid peroxidation rats orally fed high-carbohydrate and high-fat diet [17]. Son and coworkers observed the potent capacity of the seaweed to inhibit colonic aberrant Crypt Foci in experimental animals treated with azoxymethane [18]. The seaweed also reduces serum cholesterol levels in hypercholesteremic animal model [17]. Furthermore, extracts of this alga is useful in developing natural herbicidal compounds.

Components of C. fulvescens have also been proved to be biologically active. For instance, a water-soluble polysaccharide obtained from this seaweed was reported to possess antitumor activity against various human cancer cell lines including prostate (PC-3), colon (HT-29), lung (A-549), and gastric cancer cell line (MK-N-45) [19,20]. Another report claimed that polysaccharides isolated from the alga can stimulate the growth of gastrointestinal cells [21]. A group of sulfated polysaccharides from C. fulvescens also shows immunomodulatory, anti-coagulant and hepatoprotective activities in vivo [10,22].

Kim and coworkers reported that C. fulvescens-derived glycoprotein had pro-apoptotic potential on human gastric carcinoma cells [19]. Similarly, a protein purified from the seaweed demonstrated excellent antioxidant property against 2,2-diphenyl-1-picrylhydrazyl radical, hydroxyl radical, superoxide anion, and hydrogen peroxide (H$_2$O$_2$) in vitro [23]. The protein, which was obtained from the hydrophilic compartments of the seaweed, also alleviate impaired spatial memory induced by chronic ethanol exposure in vivo [24]. Another compound, phorphorbide A, from the seaweed inhibited endothelial dysfunction mediated by glycation end product formation [25].

Few reports are available in literature on the inhibitory effect of C. fulvescens and its components on enzymatic activity of proteins. Cho and colleague showed that extract from the alga can inhibit the enzymatic activity of alcohol dehydrogenase, glucosidase, elastase and angiotensin converting enzyme in vivo in a dose-dependent manner [9] while Yoo et al. [26] reveals the ability of the C. fulvescens to inhibit melanogenesis via downregulation of tyrosinase in B16 cells. These compounds also exert inhibitory effect on acetylcholinesterase as the target for their anti-neurodegenerative activity [27,28]. Although the antidiabetic potential of C. fulvescens and its constituents have been reported, there is dearth of evidence to show the precise molecular interaction with the target protein. Herein, an attempt was made to build the interaction model of antidiabetic components isolated from C. fulvescens with aldose reductase in silico towards unravelling the possible mechanisms involved in their inhibitory potential against the protein.

Materials and Methods

In silico methods used in this study has been described previously [29].

Preparation of Ligands

Briefly, a total of five ligands were selected from the literature for docking study. Out of these compounds, three are natural compounds isolated from C. fulvescens while the other two are known aldose reductase inhibitors which were adopted as reference ligands. The chemical structure of these compounds was obtained from NCBI PubChem compound database (http://www.ncbi.nlm.nih.gov/ncpchem) and prepared using MarvinSketch.

Three-dimensional optimization of the ligand structures was done using Merck molecular force field (MMFF94) before use in docking studies. The ligands were saved as MOL SD (3D) format after optimization.

Selection and Preparation of Protein Structure

The starting three dimensional (3D) structure of the proteins used in this study was downloaded from the RCSB protein data bank (http://www.rcsb.org) with PDB ID: 1EF3. The macromolecule was found in complex with fidarestat and Nicotinamide Adenosine Diphosphate (NADP). All the co-crystallized water molecules found with the protein structure and fidarestat were deleted before molecular docking procedures.

Validation of Molecular Docking Procedure

One of the major ways of validating docking procedure is to accurately regenerate both the pose and the molecular interaction of the co-crystallized ligand on the crystallographically-determined protein structure. The ligand found at the binding site of the experimentally determined aldose reductase was deleted. The structure of the ligand (sdf format) was separately prepared using Marvin sketch as described above and re-docked into the enzyme active site. The molecular interaction, majorly hydrogen bond interactions, of all the compounds were analyzed and their interaction energy calculated. The result of this analysis would help the chemist to make better choice in designing innovative new drug leads.
in this case, was compared to that of the x-ray diffraction crystal structure.

**Molecular Docking**

Autodock Vina 4.2 was used for molecular docking analysis and scoring [30,31]. The optimized ligand molecules were docked into the active site of refined model of aldose reductase. The rotatable bonds of the ligands were set to be free while the protein macromolecule was treated as a rigid structure. Grid box size was set at 100x100x100 whereas grid points were adjusted to -8.62, 40.82 and -7.18 Å (x, y, and z) to include all the amino acid residues at the binding site and permit. This gives enough space to enhance adequate ligand rotation and translation. However, the spacing between grid points was kept at 0.375 angstroms. After molecular docking experiment, the best results in terms of binding energy and pose were selected for analysis.

**Data Analysis**

All protein snapshots were taken using PYMOL while receptor-ligand molecular interaction was analysed on proteinsplus server [32].

**Results and Discussion**

![Figure 1: 3D structure of aldose reductase in cartoon and surface representation respectively showing the binding site for inhibitor fidarestat (yellow stick) and NADPH (red stick) at the active site.](image1.png)

![Figure 2: Chemical structure of the seaweed-derived compounds used as ligands in this study. (A)capsfulvesin A, (B) capsfulvesin B and (C) chalinasterol.](image2.png)

Figure 1 shows the structure of the protein, aldose reductase used as a target in the current study. Aldose reductase is an NADP-dependent enzyme which catalyzes the conversion of glucose to sorbitol in the polyol pathway. This pathway is essential because hyperglycemia, an occasion where blood glucose level becomes excessively high, can trigger an increased activity of aldose reductase which can lead to the accumulation of intracellular sorbitol. This effect has been implicated in the pathogenesis of diabetic complication such as retinopathy, neuropathy and nephropathy. Therefore, inhibition of the catalytic function of aldose reductase has been proposed as a promising therapeutic target in the prevention and treatment of type II diabetes and its associated it’s severe degenerative complications [33]. As shown in Figure 1, the enzyme active site is connected to the NADP binding pocket. This provides a chance for a ligand to potentially be a competitor of either the substrate of the coenzyme. Some natural and synthetic inhibitors of this protein have been sought over the years. Most of the reported inhibitors of aldose reductase preferably bind to the substrate binding location rather than competing with NADPH [34]. For more accurate understanding of the aldose reductase-ligand complex in the present study, two known inhibitors of the protein (fidarestat [35] and inhibitor-IDD384 [34]) were employed.
to compare the interaction pattern. The 2D chemical structure of the alga-derived ligands are given in Figure 2. Chalinasterol is a cholesterol nucleus-containing compound and it is structurally different from capsofulvesin A and capsofulvesin B which are galactolipids comprising of double aliphatic long chains with double bonds. These ligands are naturally-occurring compounds isolated from pharmacologically-important seaweed (*C. fulvescens*) [28]. It is essential to emphasize that these bioactive compounds have earlier been reported to inhibit aldose reductase *in vitro* [36]. However, the mechanism of the inhibitory effect still remains unclear.

![Figure 3: Analysis of the binding configuration of (A) chalinasterol, (B) capsofulvesin A and (C) capsofulvesin B. The binding pose for the compounds were compared against inhibitors of aldose reductase, fidarestat (green) and inhibitor-IDD384 (magenta). Areas with subtle differences in binding pose are identified in red spheres.](image)

Chalinasterol shared a comparable binding pose with inhibitor-IDD384 (Figure 3). The molecular interaction as analyzed on proteinsplus server shows the contribution of both hydrophilic and hydrophobic bonds to the stability of the complex formed by the enzyme and *C. fulvescens* compounds (Figure 4-6). The bulky steroidal rings of chalinasterol was seen deeply buried within the fidarestat-binding pocket on aldose reductase where it is participated in hydrophobic bonds while the aliphatic portion was exposed to the solvent-accessible region. Meanwhile, the inability of chalinasterol to completely block the active site may favor enzyme-substrate-chalinasterol complex formation as a mixed type of inhibition. As presented in Figure 4, two hydrogen bonds were established with amino acid residues His 110 and Trp111 respectively while Phe122, Trp219 and Trp20 participated in hydrophobic interaction with the ligand. The significance of hydrophobic bonds in the inhibition of aldose reductase cannot be overemphasized as it has been reported with many inhibitors of this protein including inhibitor IDD384. Inhibitory potential of chalinasterol against the carbohydrate-metabolizing enzyme was further proved by its binding affinity which is consistent with previous *in vitro* study that the compound possessed antidiabetic property [36,37]. The binding energy was relatively higher than that of the control ligands indicating a lower inhibitory activity for chalinasterol (Table 1). For capsofulvesin A and capsofulvesin B, the aromatic ring was placed at the solvent exposed region of the active site where it established hydrophilic interactions between its methoxyl moieties and the indole ring of Trp20 as well as the hydroxyl side chain of Ser22 (Figure 5). Possibly, the determining factor in the potency of these compounds as depicted in their IC\(_{50}\) is the binding configuration of the two long aliphatic chain. Capsofulvesin A has both of its side chain blocking the entrance to the binding cavity while one of the aliphatic chains in capsofulvesin B was found moving away from the active site (Figure 6). This elongated side chain established a unique hydrophobic bond with residue Phe122. An efficient blockage of aldose reductase active site by capsofulvesin A may alter substrate access to the protein binding site, hence interfering with the enzymatic activity. Furthermore, the extra hydrophobic bond found with Phe122 in capsofulvesin B might have hindered the possible “swinging” of the aliphatic side chain from occupying the active site. It is also not impossible that these ligands interact with the enzyme-substrate complex in a mixed type of inhibition [36]. These mechanisms possibly underline the variations in the IC\(_{50}\) values previously obtained for these compounds. The binding energy of -7.9 kcal/mol estimated for capsofulvesin A compared to capsofulvesin B (-7.7 kcal/mol) suggests a higher affinity of the former to the protein. This result is in agreement with the previous *in vitro* report showing IC\(_{50}\) values of 52.53 µM and 101.92 µM for capsofulvesin A and capsofulvesin B respectively [36]. Although seaweeds have been investigated in diabetes and its complications, only scanty reports are available for *C. fulvescens*. Among the few studies, effect of extracts from the seaweed were observed for antidiabetic activity *in vivo* using streptozotocin-induced diabetic rats [37,38]. Therefore, this study provides insights into at least a part of the mechanisms responsible for the activity.

**Citation:** Ogunwa T H. Binding Model of Antidiabetic Constituents from Capsosiphon Fulvescens with Human Aldose Reductase. Op Acc J Bio Eng & Bio Sci 1(2)· 2018. OAJBEB.MS.ID.000110. DOI: 10.32474/OAJBEB.2018.01.000110.
Table 1: Docking results showing binding energy and molecular interaction.

| Ligand            | Energy value (kcal/mol) | No of hydrogen bond formed | Residues involved in hydrogen bond formation | No of hydrophobic bond | Residues involved in hydrophobic bond formation |
|-------------------|-------------------------|---------------------------|---------------------------------------------|------------------------|-----------------------------------------------|
| Capsofulvesin A   | -8.0                    | 2                        | Ser22, Trp20                                | 3                     | Val47, Trp219, Phe122                         |
| Capsofulvesin B   | -7.7                    | 2                        | Trp20, Ser22                                | 4                     | Trp20, Val47, Trp219, Leu300, Phe122          |
| Chalinasterol     | -7.6                    | 2                        | His 110, Trp111                             | 3                     | Phe122, Trp219, Trp20                         |
| Fidarestat        | -9.0                    | 3                        | Trp20, Trp111, Tyr48                        | -                     | -                                             |
| IDD384 Inhibitor  | -9.7                    | 3                        | Tyr48, His110, Trp111                       | 1                     | Pro218                                        |

Figure 4: The binding pose and molecular interactions of chalinasterol with aldose reductase. Only key residues involved in hydrogen and hydrophobic interactions are shown as prepared on proteinsplus server.

Figure 5: The binding pose and molecular interactions of capsofulvesin A with aldose reductase. Only key residues involved in hydrogen and hydrophobic interactions are shown as prepared on proteinsplus server.

Figure 6: The binding pose and molecular interactions of capsofulvesin B with aldose reductase. Only key residues involved in hydrogen and hydrophobic interactions are shown as prepared on proteinsplus server.
Conclusion

This study investigated three antidiabetic compounds from *C. fulvescens* (a well-known green sea alga) against a diabetes-related target (aldose reductase) for their possible binding and molecular interaction pattern to provide insights into their mechanism of inhibition. With binding configurations similar to that of known inhibitors of aldose reductase, the results of the current study divulge the alga-derived compounds as suitable inhibitors of the protein. They bind at the active site and established both hydrophilic and hydrophobic bonds with some amino acid residues around site. This indicates their potential to interfere with the catalytic function of the protein. However, it was clear that the compounds did not interact with the NADP binding pocket. Hence, they are not competitive with NADPH for their inhibitory activity against aldose reductase. The subtle contrasts in the binding mode of these compounds might be responsible for the differences in their IC₅₀ values as previously reported in *in vitro* experiments. Taken together, the results of this study verify aldose reductase inhibitory activity of the *C. fulvescens* constituents and validate the antidiabetic property of the seaweed.

References

1. Dunlop M (2000) Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int 58: S3-S12.
2. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
3. Chetan S, Dharmesh SM, Mallesh NG (2008) Inhibition of aldose reductase from cataract eye lenses by finger millet (*Eleusine coracana*) polyphenols. Bioorg Med Chem 16(23): 10085-10090.
4. Ashwini DJ, Laxman NB, Tanaji AM, Madhav MJ, Akalpita UA (2016) Strong inhibition of the polyol pathway diverts glucose flux to protein glycation leading to rapid establishment of secondary complications in diabetes mellitus. *J Diabetes and Its Complications* 30(3): 298-405.
5. ZhengX, Zhang L, Zhai J, Chen Y, Luo H, et al (2012) The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase. FEBS Lett 586(1): 55-59.
6. Majee SB, Avlani D, Biswas GR (2017) Pharmacological, pharmaceutical, cosmetic and diagnostic applications of sulfated polysaccharides from marine algae and bacteria. Afr J Pharm Pharmacol 11(5): 68-77.
7. Plougiernée E, daGama BAP, Pereira RC, Barreto Berger (2014) Glycolipids from sea weeds and their potential biotechnological applications. Frontiers Cell Infect Microbiol 4(174): 1-5.
8. Cardoso SM, Pereira OR, Seca AM, Pinto DC, Silva A (2015) Seaweeds as preventive agents for cardiovascular diseases: From nutrients to functional foods. Mar Drugs 13: 6838-6865.
9. Cho EK, Yoo SK, Choi YJ (2011) Inhibitory effects of maesangii (Capsosiphon fulvescens) extracts on angiotensin converting enzyme and α-glucosidase. *Korean J Life Sci 21*: 811-818.
10. Spnytya A, Choi DJ, Pohl R, Na YS, Capel P, et al. (2015) Structural features and anti-coagulant activity of the sulphated polysaccharide SPS-CF from a green alga Capsosiphon fulvescens. *Marine Biotechnol* 17(6): 718-735.
11. Hwang EK, Amano H, Park CS (2008) Assessment of the nutritional value of Capsosiphon fulvescens (*Chlorophyta*): developing a new species of marine macroalgae for cultivation in Korea. *J Appl Phycol* 20(2): 147-151.
12. Hwang EK, Yi YH, Shin WJ, Sohn CH (2003) Growth and maturation of a green alga, Capsosiphon fulvescens, as a new candidate for seaweed cultivation in Korea, in Proceedings of the Seventeenth Chapman RO, Anderson RJ, Vreden VJ, Davison IR (Eds), International Seaweed Symposium, Oxford University Press, India p. 59-64.
13. Hwang HJ, Kim IH, Nam TJ (2011) Polysaccharides from Capsosiphon fulvescens stimulate the growth of gastrointestinal cells. *Adv Food Nutr Res* 64: 179-190.
14. Bae JM, Cho EK, Kim HY, Kang SH, Choi YJ (2012) Biological analysis of enzymatic extracts from Capsosiphon fulvescens using the microbulifer sp. Aj-3 marine bacterium. *J life sci 22(5):* 627-633.
15. Park MH, Kim MH (2005) The effect of Capsosiphon fulvescens extract on inhibition of platelet aggregation and serum lipid level in ovariectomized Rats. *J Life Sci* 15: 1028-1033.
16. Cho M, Kang JY, Won MH, Lee HS, You S (2010) The antioxidant properties of ethanol extracts and their solvent-partitioned fractions from various green seaweeds. *J Med Food* 13(5): 1232-1239.
17. Kwon MJ, Nam TJ (2006) Effects of mesangii (Capsosiphon fulvescens) powder on lipid metabolism in high cholesterol fed rats. *J Korean Soc Food Sci Nutr* 35(5): 530-535.
18. Son Y, Ullah HMA, Bifat AK, Ghim S, Chung M, et al. (2018) Inhibition of formation of acetoxyurethane-induced colonic aberrant crypt foci in rats by edible green alga Capsosiphon fulvescens and brown alga Hizikia fusiforme. in vivo 32: 101-108.
19. Kim YM, Kim IH, Nam TJ (2012) Induction of apoptosis signaling by glycoprotein of Capsosiphon fulvescens in human gastric cancer (AGS) cells. *Nutr Cancer 64(5):* 761-769.
20. Kwon M, Nam T (2007) A polysaccharide of the marine alga Capsosiphon fulvescens induces apoptosis in AGS gastric cancer cells via an IGF-IR-mediated PI3K/Akt pathway. *Cell Biol Int* 31(9): 768-775.
21. Hwang HJ, Kim IH, Nam TJ (2011) Polysaccharides from Capsosiphon fulvescens stimulate the growth of gastrointestinal cells. *Adv Food Nutr Res* 64: 179-190.
22. Karnjanapratum S, Tarsaba M, Cho M, You S (2012) Characterization and immunomodulatory activities of sulfated polysaccharides from Capsosiphon fulvescens. *Int J Macromol* 51(5): 720-729.
23. Kim EY, Choi YH, Lee JI, Kim IH, Nam TJ (2015) Antioxidant activity of oxygen evolving enhancer protein 1 purified from Capsosiphon fulvescens. *J Food Sci Biotech* 80(6): 1412-1417.
24. Kim E, Nam T, Oh JH (2017) Hydrophobic compartments of Capsosiphon fulvescens protein alleviate impaired spatial memory by regulating BDNF-mediated ER stress against chronic ethanol exposure. *J Functional Foods* 35: 474-480.
25. Hong C, Nam M, Oh J, Lee J, Kim C, et al. (2016) Phosphorhodamine A from Capsosiphon fulvescens inhibits advanced glycation end products mediated endothelial dysfunction. *Planta Med* 82(1-2): 46-57.
26. Yoo HJ, Jo MG, Park SJ, Mun YJ, Pyo HB, et al. (2007) Capsosiphon fulvescens decreases melanin synthesis via downregulation of tyrosinase and TRP-2 expression. *Korean J Oriental physiol Patho* 21(4): 998-1003.
27. Fang Z, Jeong SY, Choi JS, Min BS, Min BK, Woo MH (2012) Cholinesterase inhibitory constituents from Capsosiphon fulvescens. *Nat Prod Res* 64: 179-190.
28. Fang Z, Jeong SY, Jung HA, Choi JS, Min BS, et al. (2012) Capsosiphonfulvescines A-C, cholinesterase inhibitors from Capsosiphon fulvescens. *Chem Pharm Bull* 60(11): 1351-1358.
29. Ogunwa TH, Ayanjolah AC (2013) An insight into the precise molecular interaction and inhibitory potential of fumagilin b and its substituted derivatives on human α-amylase. *Arch Curr Res Int* 1(1): 1-14.
30. Trott O, Olson AJ (2010) Auto Dock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31(2): 455-461.

31. Seelinger D, de Groot BL (2010) Ligand docking and binding site analysis with PYMOL and Autodock/Vina. J Comput Aided Mol Des 24(5): 417-422.

32. Fricker P, Gastreich M, Rarey M (2004) Automated Generation of Structural Molecular Formulas under Constraints. J Chem Inf Comput Sci 44(3): 1065-1078.

33. Ramirez MA, BorjaNL (2008) Epalrestat: An aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacother 28(5): 646-655.

34. Calderone V, Chevrier B, Van Zandt M, Lamour V, Howard E, et al. (2000) The structure of human aldose reductase bound to the inhibitor IDD384. Acta Crystallogr D Biol Crystallogr 56: 536-540.

35. El Kabbani O, Darmanin C, Oka M, Schulze Briese C, Tomizaki T, et al. (2004) High-resolution structures of human aldose reductase holoenzyme in complex with stereoisomers of the potent inhibitor Fidarestat: stereospecific interaction between the enzyme and a cyclic imide type inhibitor. J Med Chem 47(18): 4530-4537.

36. Islam MN, Choi SH, Moon HE, Park JI, Jung HA, et al. (2014) The inhibitory activities of the edible green alga Capsosiphon fulvescens on rat lens aldose reductase and advanced glycation end products formation. Eur J Nutr 53(1): 233-242.

37. Tong T, Zhang C, Ko DO, Kim SB, Jung KJ et al. (2014) Effects of the addition of Hizikia fusiforme, Capsosiphon fulvescens, and Undaria pinnatifida sporophyll on antioxidant and inhibitory potential against enzymes related to type 2 diabetes of vegetable extract. Korean J Food Preserv 21: 460-467.

38. Lee K, Kim S, Oh J, Nam M, Hong C (2014) Hepato-protective and anti-diabetic effects of Capsosiphon fulvescens and pheophorbide A in streptozotocin-induced diabetic rats. Toxicol Lett 229(S242): 119.